Richard Young Buys 16,378 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Director Richard Young bought 16,378 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average price of $1.65 per share, for a total transaction of $27,023.70. Following the completion of the transaction, the director directly owned 186,388 shares of the company’s stock, valued at $307,540.20. This represents a 9.63% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.

CAMP4 Therapeutics Price Performance

NASDAQ CAMP opened at $4.50 on Friday. CAMP4 Therapeutics Corporation has a 1-year low of $1.32 and a 1-year high of $7.75. The business has a 50 day simple moving average of $4.02 and a two-hundred day simple moving average of $4.31. The stock has a market capitalization of $233.69 million, a PE ratio of -1.91 and a beta of 0.22.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.11). The firm had revenue of $1.29 million for the quarter. CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. On average, analysts anticipate that CAMP4 Therapeutics Corporation will post -0.84 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on CAMP. Zacks Research lowered CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 15th. Rodman & Renshaw initiated coverage on CAMP4 Therapeutics in a report on Tuesday, April 14th. They issued a “buy” rating and a $7.00 target price for the company. Chardan Capital set a $6.50 target price on CAMP4 Therapeutics and gave the company a “buy” rating in a research report on Wednesday, June 10th. Weiss Ratings lowered CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 21st. Finally, JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $5.00 to $9.00 in a research report on Tuesday, June 16th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $8.36.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Bridgeway Capital Management LLC bought a new stake in shares of CAMP4 Therapeutics during the 2nd quarter worth approximately $36,000. China Universal Asset Management Co. Ltd. purchased a new stake in CAMP4 Therapeutics in the fourth quarter worth $61,000. Jefferies Financial Group Inc. purchased a new stake in CAMP4 Therapeutics in the fourth quarter worth $70,000. Bank of America Corp DE bought a new stake in shares of CAMP4 Therapeutics during the fourth quarter worth $86,000. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of CAMP4 Therapeutics during the fourth quarter valued at $115,000.

Key Stories Impacting CAMP4 Therapeutics

Here are the key news stories impacting CAMP4 Therapeutics this week:

• Positive Sentiment: CMP-002 is advancing into human trials. CAMP4 received regulatory clearance in Australia and Argentina to begin a Phase 1/2 study of CMP-002, an antisense oligonucleotide therapy for SYNGAP1-related disorders. The double-blind, placebo-controlled trial is expected to enroll at least 30 children ages 2 to 18. This is a significant milestone because SYNGAP1-related disorder has no approved disease-modifying treatments. CAMP4 advances SYNGAP1 treatment into human trials
• Positive Sentiment: Insider buying may signal management confidence. CEO Josh Mandel-Brehm, CFO Kelly Gold, Director Richard A. Young and insider Yuri Maricich collectively bought 36,031 shares at an average price of $1.65. While the purchases were modest in dollar value, they increased the insiders’ ownership positions and may be viewed positively by investors. CAMP4 insider purchase filing
• Positive Sentiment: Recent financing improves development funding. CAMP4 raised approximately $50.1 million in the second closing of a private placement. The proceeds are intended to support CMP-002 and the company’s early-stage pipeline, with participation from institutional investors including Janus Henderson, Balyasny Asset Management, Vivo Capital and 5AM Ventures. CAMP4 private placement announcement
• Negative Sentiment: The capital raise is significantly dilutive. CAMP4 issued more than 10.7 million common shares and approximately 21.9 million pre-funded warrants at about $1.53 per share-equivalent. The expanded potential share count and discounted issuance could limit per-share upside despite extending the company’s cash runway.
• Neutral Sentiment: Clinical risk remains high. CMP-002’s move into a Phase 1/2 trial is encouraging, but the therapy is still investigational. Safety and efficacy results in humans could differ materially from preclinical findings, making future trial updates key catalysts for CAMP.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.